Steven M. Chaouki - Aug 1, 2022 Form 4 Insider Report for MAIA Biotechnology, Inc. (MAIA)

Role: Director
Signature: /s/ Steven Chaouki
Stock symbol: MAIA
Transactions as of: Aug 1, 2022
Transactions value $: $25,000
Form type: 4
Date filed: 8/2/2022, 06:33 PM
Previous filing: Jul 27, 2022
Next filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MAIA	Common Stock	Purchase	$25K	+5K	+12.12%	$5.00	46.3K	Aug 1, 2022	Direct	F1
transaction	MAIA	Common Stock	Other		+8K	+17.3%		54.3K	Aug 1, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were purchased in the initial public offering (the "IPO") of MAIA Biotechnology, Inc. (the "Issuer"), which closed on August 1, 2022.
F2	In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 10,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 8,000 shares of Common Stock for no additional consideration.

Content

These shares were purchased in the initial public offering (the "IPO") of MAIA Biotechnology, Inc. (the "Issuer"), which closed on August 1, 2022.

In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 10,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 8,000 shares of Common Stock for no additional consideration.